Skip to main content
. 2020 Mar 4;10(9):3952–3966. doi: 10.7150/thno.39578

Figure 6.

Figure 6

miR-378a-3p increased the rate of VLDL production in mice. (A) Levels of miR-378a-3p and Sort1 mRNA in livers of mice treated with MC-TTR-miR-378a (n=9) or MC-TTR-miR-378a-MM (control, n=9). (B) Increased rate of VLDL production in mice treated with MC-TTR-miR-378a. The difference between baseline and 1-hour plasma TG levels was measured after Triton WR1339 treatment. (C) Increased 35S-methionine/cysteine-labeled ApoB100 in the blood of mice treated MC-TTR-miR-378a. (D) Increased VLDL-TG in pooled plasma of mice treated with MC-TTR-miR-378a. Plasma lipoprotein triglyceride distribution was determined by FPLC. (E) Increased levels of total plasma triglycerides in mice treated with MC-TTR-miR-378a before and after injection of Triton WR1339. Data represent mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.001 (Mann-Whitney test).